Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sean McCutcheon
RJ
Sean McCutcheon
Raymond James
Wall Street Analyst
★★★☆☆
#1198
on 13Foresight · ranked by our own returns
54%
Success Rate
+13.4%
Average Return
7 of 13 calls profitable · +0.7% vs benchmark
📈 Across the calls we could measure, roughly 54% of Sean McCutcheon's ratings turned a profit when each position was held for 1 year — averaging +13.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

20 Buy 4 Hold 0 Sell
Sean's Stock Coverage 14 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
RLAY
Relay Therapeutics
 May 19, 2026 BUY Strong Buy
+26.5% avg upside
19 analysts
$26.00
63.75% Upside
 +31.3%
ENGN
enGene Holdings
 May 08, 2026 BUY Buy
+478.3% avg upside
13 analysts
$4.00
132.50% Upside
 +16.7%
CMPX
Compass Therapeutics
 Apr 28, 2026 HOLD Strong Buy
+372.3% avg upside
19 analysts
 — +1.2%
VIR
Vir Biotechnology
 Feb 24, 2026 BUY Strong Buy
+185.4% avg upside
16 analysts
$19.00
107.33% Upside
 -9.3%
BBOT
BridgeBio Oncology Therapeutics
 Jan 09, 2026 BUY Strong Buy
+231.7% avg upside
10 analysts
$24.00
217.37% Upside
 -41.8%
RVMD
Revolution Medicines
 Oct 17, 2025 BUY Strong Buy
-12.2% avg upside
32 analysts
$76.00
53.47% Downside
 +191.6%
BDTX
Black Diamond Therapeutics
 Sep 10, 2025 BUY Strong Buy
+987.8% avg upside
12 analysts
$11.00
562.59% Upside
 -14.3%
RGNX
RegenXBio
 Sep 05, 2025 BUY Strong Buy
+381.2% avg upside
22 analysts
$29.00
271.77% Upside
 -41.1%
XNCR
Xencor
 Aug 07, 2025 BUY Strong Buy
+159.5% avg upside
27 analysts
$40.00
216.44% Upside
 +54.0%
LKFT
Lakefront Biotherapeutics
 Jul 24, 2025 HOLD Hold
+272.9% avg upside
24 analysts
 — ·
REGN
Regeneron
 Jul 17, 2025 HOLD Strong Buy
+26.9% avg upside
57 analysts
 — +12.4%
BMY
Bristol-Myers Squibb
 Jul 17, 2025 HOLD Buy
+9.1% avg upside
42 analysts
 — +19.2%
JANX
Janux Therapeutics Inc
 Jul 11, 2025 BUY Strong Buy
+217.9% avg upside
21 analysts
$65.00
357.17% Upside
 -43.7%
LEGN
Legend Biotech
 Jun 13, 2025 BUY Strong Buy
+134.2% avg upside
27 analysts
$86.00
207.86% Upside
 -2.6%
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sean McCutcheon — Frequently Asked Questions
How accurate are Sean McCutcheon's stock ratings?
Based on the calls 13Foresight could measure, about 54% of Sean's ratings were profitable over a one-year hold, with an average return of +13.4% per rating, or +0.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Sean ranked on 13Foresight?
Sean McCutcheon is currently ranked #1198 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sean cover?
Sean most recently has ratings on RLAY, ENGN, CMPX, VIR, BBOT, RVMD, BDTX, RGNX, XNCR, LKFT, REGN, BMY and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.